In vitro activity of ciprofloxacin against multiresistant microorganisms isolated from cases of hospital infection
Caiaffa Filho, H.H.; Mendes, C.M.
Amb Revista da Associacao Medica Brasileira 33(5-6): 99-102
1996
ISSN/ISBN: 0102-843X PMID: 3129763 Document Number: 787
The "in vitro" ciprofloxacin activity of 600 multiresistant (MRB) clinical isolates, with resistance against two or more no related antimicrobial agents usually susceptible, was studied Enterobacteriaceae (EB) 350; E. coli (100); Enterobacter - Citrobacter-Serratia (100); Klebsiella pneumoniae (50); Morganella - Providencia (50); Proteus mirabilis (50). The other 250 isolates: Pseudomonas aeruginosa (50); Acinetobacter baumannii (50); Methicillin-resistant Staphylococcus aureus and Coagulase Negative Staphylococcus (100) Enterococcus faecalis (30) and Enterococcus faecium (20), were successively incorporated. The Ciprofloxacin R achieved 14% among EB, with a range 4-22% among Kp and Mg respectively. E. coli CIP resistance was 5%. The Ciprofloxacin-resistance achieved 14% among Enterobacteriaceae, range 4-22% among K. pneumoniae and Morganella morganii, respectively, among E. coli was 5%, notwithstanding nearly all were either high TEM-type beta-lactamase extended spectrum beta-lactamase or derepressed chromosomic beta-lactamase producers, besides partial or total resistance to aminoglycosides. The imipenem-resistance was 0.2% in this group. The Ciprofloxacin-resistance among P. aeruginosa and Acinetobacter baumannii was 36 and 66% respectively and imipenem-resistance, 4-12%. The highest Ciprofloxacin resistance, 74 and 78%, was detected among MRSA and MRCNS, respectively. In conclusion, the 'in vitro' Ciprofloxacin-resistance among Enterobacteriaceae is acceptable unlike those of NFGNB and gram positive cocci. The Ciprofloxacin treatment of infections due to these microorganisms must be controlled and would be used with other antimicrobial agents, mainly amino or acilureidopenicillins.
Document emailed within 1 workday
